What's New in Research Funding

Molecular structuresPage last updated August 10, 2018

We are pleased to assist the research community in identifying potential sources of funding through the provision of information posted here:

  • All Applicants submitting through the University of Toronto MUST have submitted their application information online via the My Research Applications (MRA) portal. This is an online submission process to obtain institutional approval on research applications. Please note that you will be required to upload a copy of the application to this online submission. Please complete this step as early as possible and at least several days ahead of the deadline to insure all approvals are obtained on time. Please visit the OVPRI's MRA webpage for complete information on this process.
  • Please note, all grants requiring the Dean's signature should be brought to the Faculty of Medicine Research Office in the Medical Sciences Building, Room 2331 to the attention of Cindy Faber cindy.faber@utoronto.ca.
  • Also, our office offers a grant editing service for researchers submitting proposals to tri-council or any other funding agency. For more information, please contact dan.harney@utoronto.ca.
  • Recently received news and updates are posted below and sent via email to our LISTSERV. To join click here.

Comprehensive funding opportunities may be searched through these links:

Recently Received News and Updates:


August 10, 2018

  • CIHR Information Session (hosted by the University of Toronto). The Research Services Office will hold an information session on the upcoming CIHR Foundation and Project grant competitions for Fall 2018.
    The session will cover program and eligibility requirements, changes for the 2018 competitions, navigating the ResearchNet and Canadian Common CV (CCV) systems, and other tips for submitting a strong application. Expert guest speaker Dr. Leah Cowen, Professor in the Department of Molecular Genetics, will provide insight into the application process and elements of a strong proposal through the lens of both a successful grantee and past reviewer.
    Please RSVP by no later than 12:00 p.m. on Wednesday, August 15th to Rocket Ship Weir at rs.weir@utoronto.ca.  Space is limited, so please be sure to RSVP as soon as possible. Please note there is a remote access option. Details can be found here
    DATE: Friday, August 17, 2018 from 1pm-2:30pm.
    Location: University of Toronto Bahen Centre, Room 1130, 40 St. George Street
  • 2018 NSERC Discovery Grant and RTI Information Sessions (hosted by the University of Toronto). We are pleased to offer Information Sessions to UofT faculty applying to this fall's NSERC Discovery Grant program or this fall's NSERC RTI Grant program. Topics will include each program's application requirements, eligibility, changes for this year’s competitions, evaluation criteria and proposal development.  These sessions will also include guest speakers (committee member or a successful applicant) who will outline details in the application and evaluation process.
    The Discovery Grant and RTI Info Sessions will be held on the following dates and locations: 
    St. George - Discovery only: September 5 from 1pm-3pm. Galbraith Building, Room 119, 35 St. George Street.
    St. George - RTI only: September 8 from 1pm - 2:30pm. VPRES McMurrich Meeting Room, 1st floor, 12 Queen's Park Crescent West.
    Visit here for further details and registration information, as well as for UTM and UTSC dates and locations.
  • Canada Research Coordinating Committee (CRCC): Consultation. The CRCC is launching a national consultation to reinvigorate Canada’s support for science and to position Canada as a global leader in research excellence. 
    This is an opportunity for Canadians, the research community and the next generation of scientists, scholars and students to help shape research in Canada. The vision for the future of Canada's research landscape is a bold, world-leading and highly coordinated system of federal support for science—a system that contributes to the social and economic well-being of Canadians.
    Share your views
    The CRCC invites your feedback on three key priorities:
    •    A new Tri-Agency Research Fund
    •    Strengthening equity, diversity and inclusion in research
    •    Support for early career researchers
    To learn more about each of these priorities, visit here.
    The initial consultation will close on August 27, 2018, and results will be shared shortly after this date for a further consultation.
  • REMINDER: NEW! ECHO (Entrepreneurship for Cardiovascular Health Opportunity) The Translational Biology & Engineering Program (TBEP) in partnership with the Health Innovation Hub (H2i) at the University of Toronto. ECHO is a specialized hands-on training program led by veteran entrepreneurs and consultants across a variety of sectors. ECHO provides innovators of cardiovascular technologies with entrepreneurship training, mentorship, networking, and funding opportunities. Any Canadian-based student, researcher and/or entrepreneur developing advanced cardiovascular technologies and innovations is encouraged to apply. Deadline for applications: Friday, August 24, 2018.
  • University of Toronto - Connaught Innovation Award 2018-19. Approximately, 10-12 awards of up to $50,000 will be allocated in the 2018-19 competition to accelerate the development of promising technology and promote commercialization and/or knowledge transfer.  This year, Connaught applications will be at or above Technology Readiness Level (TRL) 4 as defined by Science and Economic Development Canada (SEDC) to support evolving the innovation to the next level with potential commercial partners.  Information regarding SEDC TRL Scale can be found here.  Successful projects will have strong socio-economic and/or commercial potential, and will strive to have a positive impact on society. For each project, a Notice of Intent (NOI) must be submitted to the Connaught Secretariat by September 10, 2018. Full applications are due by October 15, 2018. Projects must be based on inventions or research discoveries that are already disclosed to the University as of August 27, 2018. Full program details and application materials can be found on the Connaught Innovation Award page.
  • PSI Graham Farquharson Knowledge Translation Fellowship 2019. This Fellowship is intended to provide salary support for a new Ontario investigator, who has demonstrated the ability to successfully complete high impact knowledge translation research. The Fellowship’s funds, dedicated to salary support, must protect at least 50% of the Fellow’s time to conduct such research. All applications for this funding opportunity must be made through the Faculty of Medicine Research Office and are subject to internal review. All applications must include the completed PSIF application form and adhere to the guidelines provided. Only two applications will be selected for submission and formally endorsed by the institution. Faculty of Medicine, UofT internal deadline: Thursday, October 11, 2018 at 9am. See our webpage for eligibility, guidelines, and how to apply. Further information and to see examples, please see PSI's website.
  • PSI Research Trainee Fellowship 2019. The primary aim of this fellowship is to provide highly qualified Medical Doctors (M.D.) with clinically applicable research training opportunities and support. (Please note: this funding opportunity is not an additional PSI operating grant.). Applicants must be an M.D. in a Ph.D. or MSc. Program, or in a combined M.D./Ph.D. or MSc. Program, or In the Clinician Investigator Program (CIP). All applications for this funding opportunity must be made through the Faculty of Medicine Research Office and are subject to internal review. All applications must include the completed PSIF application form and adhere to the guidelines provided. Only two applications will be selected for submission and formally endorsed by the institution. Faculty of Medicine, UofT internal deadline: Tuesday, October 9, 2018 at 9am. See our webpage for eligibility, guidelines, and how to apply. Further information and to see examples, please see PSI's website.

  • CIHR Doctoral Awards. For this competition, applications will be accepted in all areas of health research, including biomedical, clinical, health services and social, cultural, environmental and population health.
    - Internal deadline for UofT applicants: September 25, 2018. (MRA needed from applicant's supervisor)
    - ResearchNet deadline for sponsor assessments: 48 hours prior to the CIHR deadline of October 2, 2018.
    PLEASE NOTE: The internal MRA requirement is for all applicants applying for this award through the University of Toronto. For all other applicants, please contact the Research Office of the institution through which you are applying.
    CIHR INFORMATION SESSION for students: English: September 11, 2018 at 11am EST; French: September 12, 2018 at 11am EST. Register here.

  • CIHR Fellowship Awards. These awards provide support for highly qualified candidates at the post-PhD or post-health professional degree stages to add to their experience by engaging in health research either in Canada or abroad. For this competition, applications will be accepted in all areas of health research, including biomedical, clinical, health services and social, cultural, environmental and population health.
    - Internal deadline for UofT applicants: October 25, 2018. (MRA needed from applicant's supervisor)
    - ResearchNet deadline for sponsor assessments: 48 hours prior to the CIHR deadline of November 1, 2018.
    PLEASE NOTE: The internal MRA requirement is for all applicants applying for this award through the University of Toronto. For all other applicants, please contact the Research Office of the institution through which you are applying.
    CIHR INFORMATION SESSION for students: English: September 11, 2018 at 11am EST; French: September 12, 2018 at 11am EST. Register here.

  • Genome Canada: Genomic Applications Partnership Program (GAPP) Round 13. *NEW* Precision Health Initiative - Rare Diseases: Clinical Implementation Projects. 
    Genome Canada has launched a national initiative for the clinical implementation of precision health, focusing on a rare disease pilot program as a foundational step. In order to initiate this ambitious program, Genome Canada is encouraging the submission of projects to the GAPP. Details, timelines, and how to apply can be found on the  GAPP homepage or the UofT funding opportunity. Deadline for draft expressions of interest: August 20, 2018 (due at UofT Research Services Office and Ontario Genomics). Applicants interested in applying are encouraged to contact Shobha Ramsubir, Senior Manager, Business Development and Outreach at Ontario Genomics. 

  • The Kidney Foundation of Canada:
    - 2019 Biomedical Research Grant Competition. Biomedical Research Grants provide financial support to medical researchers to assist in defraying the operating costs of research, which may include the purchase of materials, supplies and equipment and the payment of laboratory assistants. Grants are available for one, two or three years, commencing July 1, for up to $50,000 per year. 
    - Special Research Project Grant:  Predictive Biomarkers. Applicants are invited to submit a proposal for a special project related to predictive biomarkers.  The value of this grant is $450,000 over 4 years, with a maximum of $112,500 per year.
    Registration deadline: September 1, 2018; Full application deadline: October 1, 2018.

  • Cystic Fibrosis Canada: 2018 Fall Research Competition. Cystic Fibrosis is now accepting applications for the following awards:
    - Early Career Investigator award
    - Fellowship award
    - Studentship award
    Internal deadline for UofT applicants: September 24, 2018. (MRA needed from applicant's supervisor)
    Cystic Fibrosis Canada's deadline for final applications on proposalCENTRAL: October 1, 2018.

  • Grand Challenges Canada: Stars in Global Health - Sexual & Reproductive Health and Rights. Through this initiative Grand Challenges Canada is seeking bold ideas for products, services and implementation models that could transform how persistent challenges in sexual and reproductive health and rights are addressed in low- and middle-income countries. The bold ideas are expected to improve the provision and use of comprehensive sexual and reproductive health services. Of particular interest to Grand Challenges Canada are innovations that both prevent and respond to: Sexual and gender-based violence; Child, early, and forced marriage. Amount $100,000 for up to 12 months. UofT Internal deadline: September 18, 2018; Sponsor deadline: September 20, 2018.

  • Westin Brain Institute: Upcoming webinars:
    Quantum and Watson for Drug discovery - presented by IBM:
    August 21, 11am - 1pm EDT. Register here.
    Collaborating with CDRD on the preclinical development of novel therapeutics in neuroscience:
    September 14, 3pm-4pm EDT. Register here.

  • Hepatology Research Fellowship. Fall 2018 Priority Announcement. The CIHR -INMD in partnership with the Canadian Association for the Study of Liver (CASL) and the Canadian Liver Foundation (CLF), will provide funding for applications that are determined to be relevant to the following research priority:  Project proposals involving clinical and/or basic research that will advance the understanding of liver disease and ultimately contribute to patient management and care in Canada. Deadline for applications: November 1, 2018.

  • Crohn`s and Colitis Foundation of America Inc. (CCFA): Biology of Fibrosis in IBD. The CCFA seeks to fund studies focused on investigating the biological mechanisms leading to, and protecting from, fibrosis in IBD. These studies should be built upon clinical observations and/or published evidence in human IBD. Particular interest will be on proposals that address one or more of the following areas: 
    - Pathophysiology of fibrosis based on documented patterns of gene expression 
    - Cell biological mechanisms of fibrosis - role of different cell types 
    - Biology of strictureplasty 
    A multidisciplinary approach is preferred, for example, studies including in vitro models (e.g. human intestinal organoids), analysis of human biopsies, animal models of fibrosis, biophysical studies, and imaging approaches. Upper amount USD $900,000 over 3 years. Deadline for applications: September 7, 2018.

  • Michael J. Fox Foundation for Parkinson Research (MJJF).
    - Target Advancement Program. These awards support research characterizing promising, novel PD-relevant targets or continuing target biology work on established PD targets. Preferred targets for this program already demonstrate links to PD in human patient populations. These awards are well-suited to projects in which hypothetical or experimental rationale for a target is compelling but limited, and study results can make the case for continuing (or discontinuing) a line of research. Funding available: 12 - 18 months grants up to USD $150,000.
    - Therapeutic Pipeline Program. The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications. Therapeutic Pipeline awards support prospective studies or retrospective studies utilizing existing data in human biofluids. Funding available: Pre-Clinical - USD $100K - $500K, one to two-year grants. Clinical - USD $1M-$2M, two to three-year grants.
    Funding Opportunities Information WEBINAR: September 6 at 12pm. Register here.
    Deadline for preliminary proposals: September 26, 2018.

  • BrightFocus Foundation: Standard Research Grants. These awards provide significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to government or industrial agencies.
    - Alzheimer`s Disease Research Standard Award. Amount: USD $300,000 over 3 years. Deadline for applications: October 2, 2018.
    - National Glaucoma Research Standard Award. Amount: USD $200,000 over 2 years. Deadline for applications: November 9, 2018. 

  • Angelman Syndrome Foundation: Open call for research proposals. Angelman syndrome is a neurodevelopmental disorder caused by deficiency of the ubiquitin protein ligase UBE3A in the brain. Applications in the preclinical, translational and clinical research areas that investigate all aspects of Angelman syndrome will be considered. Highest priority will be given to pilot projects to test new ideas about pathogenesis and therapeutics of Angelman syndrome, translational research and clinical research studies. Of particular interest to the ASF are studies related to communication, behavioral issues and identification of issues and treatments that impact the daily life of people with Angelman syndrome and their families. Amount: Up to USD $100K per year for up to two years. Deadline for applications: October 15, 2018.

  • Scleroderma Foundation: Established Investigator Grants. The Scleroderma Foundation seeks applications from promising established investigators both inside and outside the field of scleroderma research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to the disease. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources. Amount: Up to USD $75K per year for up to two years (including 8% indirect costs). Deadline for applications: September 15, 2018.


July 25, 2018

  • Launch of CIHR Project Grants Competition - Fall 2018The Project Grant program is open to applicants in all areas of research that align with its mandate
    Mandatory registration deadline: August 15, 2018
    UofT internal application deadline (My Research Applications): September 5, 2018;
    External application deadline (ResearchNet): September 12, 2018.
    INFORMATION WEBINARS: CIHR will host a number of webinars. Please visit their website for dates and times, and to register.
  • Launch of CIHR 2018-2019 Foundation Grant competition. The Foundation Grant program is designed to contribute to a sustainable foundation of established health research leaders, by providing long-term support for the pursuit of innovative, high-impact programs of research. Programs of research are expected to include integrated, thematically-linked research, knowledge translation and mentoring/training components.
    The Foundation Grant program is supported by a multi-stage competition and review process. Only successful Stage 1 applicants will be invited by CIHR to submit an application for Stage 2.
    Mandatory registration deadline: August 15, 2018
    UofT internal Stage 1 application deadline (My Research Applications): September 12, 2018;
    External Stage 1 application deadline (ResearchNet): September 19, 2018.
    INFORMATION WEBINARS: CIHR will host a number of webinars. Please visit their website for dates and times, and to register.
  • CIHR Pre-announcement: Transitions in Care Team Grants. CIHR has designed a new funding opportunity to address improved health and wellness by transforming health systems for optimized outcomes for individuals experiencing transitions in care. The Team Grants are component 4 under the CIHR TiC multi-Institute initiative. 
    WEBINAR: September 4, 2018 3:00 – 4:00 pm EDT.  Register here.
  • Banting & Best Diabetes Centre (BBDC) Sun Life Financial Investigator Award for Diabetes Research 2018-2019This award is intended to support new clinician-scientists and basic scientists in the early stages of their careers. One Sun Life Financial New Investigator Award will be made available for this competition. Funds may be used for diabetes research support and/or the salary of a clinician-scientist conducting diabetes research.  
    For eligibility criteria, complete award details and application instructions, please visit their website. Questions should be directed to Rose LaBarbera at diabetes.bbdc@utoronto.ca, Tel: 416-978-4465.
    Deadline for applications: October 23, 2018 at 4pm.
  • Heart & Stroke Foundation: Grants-in-Aid (GIA) Program. GAI funding promotes research discovery, exploration and innovation across all health research themes. Knowledge gained from scientific findings, contributes to the cardiovascular and cerebrovascular health of Canadians through prevention, treatment and recovery. Research is supported across the four health research themes: 1) Basic Biomedical, 2) Clinical, 3) Health Service/Systems, 4) Social, Cultural, Environmental and Population Health. Deadline for applications: August 30, 2018 at 4pm EDT. Visit here to view HSF's upcoming personnel awards.
  • The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program. This program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.
    The research program will support studies that aim to:
    •  Identify and provide insight into key issues associated with the ageing hemophilia population
    •  Identify how management of age-related co-morbidities should be adapted to those with hemophilia
    •  Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia
    Amount: a maximum of $60,000 for up to 1 year. Deadline for applications: August 31, 2018.
  • Simons Foundation Autism Research Initiative - 2018 Pilot Grants. Pilot Grants support innovative, high-impact, proposals requesting support for small-scale projects or early-stage experiments that build on preliminary data. The maximum budget is $300,000 USD (including 20% indirect costs) for up to 2 years. Areas of interest include genetics and other factors contributing to risk; molecular and cellular mechanisms; synaptic and circuit physiology; sensory perception; cognition; behaviour; and clinical and translational studies. Sponsor deadline: September 14, 2018.
  • Alzheimer's Association, ARUK, MJFF, and the Weston Brain Institute: Biomarkers Across Neurodegenerative Diseases (BAND). The main objective of BAND is to stimulate analyses across Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases to increase understanding of pathogenesis similarities and differences. The intent of this RFA is to analyze across existing data; biological samples are not available for use under this RFA. Funding from this program may support but is not limited to projects that aim to develop and/or advance innovative data models, biomarker discovery, assay standardization, genetic profiling, harmonize existing data set phenotypes, analyze cross-disease or longitudinal analyses of existing data, inclusion of other neurodegenerative diseases related to PD and AD, or imaging development. Applications are encouraged from research laboratories and teams around the world. Upper amount: $150,000 USD for up to two years. 
    Informational Conference Call (Sandpit/Briefing Session): August 20, 2018 at 12pm ET. To receive call-in details, RSVP to conferencecalls@michaeljfox.org.
    Deadline for Letters of Intent: September 10, 2018; Application deadline: December 1, 2018.
  • Leukemia & Lymphoma Society (LLS): Pediatric Blood Cancer Research Initiative. (NEW). LLS's Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects. A major focus is translatability to the clinic within the time frame of the SCOR, or shortly after the grant term ends. LLS welcomes applications from both US citizens and non-citizens, as well as applicants who are performing research outside the U.S. Upper amount: $5,000,000 USD over five years. Deadline for Letters of Intent: August 31, 2018 at 3pm ET.
  • U.S. Department of Defense: Breast Cancer Research Program (BCRP) - Breakthrough Award - Levels 3 and 4 (NEW). The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. All organizations, including international organizations, are eligible to apply. Upper amount: $10,000,000 USD; Lower amount: $2,500,000 USD. Deadline for pre-applications: September 14, 2018 at 4pm ET.
  • Alpha-1 Foundation.
    • Pilot and Feasibility Grants. The objective of this grant is to provide funds to encourage the development and testing of new hypotheses and/or new methods in research areas relevant to AAT Deficiency. Proposed work must be hypothesis generating or hypothesis testing, reflecting innovative approaches to important questions in AAT research or development of novel methods, and providing sufficient preliminary data to justify the Foundation's support. Upper amount $75,000 USD for up to one year. Deadline for Letters of Intent: September 28, 2018.
    • Research Grants. The objective of this grant is to provide funds to encourage the development of new information that contributes to the understanding of the basic biology of alpha-1 antitrypsin expression, and the pathogenesis/management of AAT Deficiency. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to new therapies for AAT Deficiency. Deadline for Letters of Intent: September 28, 2018.
  • World Health Organization (WHO): Polio Research Committee's call for proposals (Collaborative Research Project). The Polio Research Committee is calling for research proposals supporting the Polio Eradication & Endgame Strategic Plan 2013-2018. The current priority of the Polio Research Committee is to generate new data or information in the following areas: 1) Vaccine schedule immunogenicity, 2) Surveillance, 3) Product development, 4) Epidemiology/virology, 5) Monitoring & evaluation, 5) Basic immunology. Upper amount: $300,000 CHF; Lower amount: $50,000 CHF. This call for proposals is open to research institutions and private companies. Deadline for proposals: September 15, 2018.
  • National Eczema Association (NEA). The NEA is now soliciting original, focused and innovative eczema research applications dealing with atopic dermatitis. Please visit their website to view their 2018 research priorities.  Applications will be accepted from around the world. Upper amount: $75,000 USD over one year. Deadline for applications: September 14, 2018.
  • ASXL Rare Research Endowment Foundation (ARRE): Request for Basic Scientific & Clinical Research Proposals. The ASXL family consists of ASXL1/Bohring-Opitz Syndrome, ASXL2/Shashi-Pena Syndrome, and ASXL3/Bainbridge-Ropers Syndrome. ARRE will support basic scientific and clinical research that can further characterize the molecular causes and pathogenicity of the ASXL gene family, improve medical care plans, and meet the needs for families who face extraordinary challenges and uncertainty. Highest priority will be given to pilot projects to test new ideas about pathogenesis and therapeutics of ASXL congenital syndromes and clinical research studies. Of particular interest to the ARRE are studies related to respiratory illness, cyclic vomiting, seizures, sleep issues, and identification of treatments that impact the daily life of people with ASXL syndromes and their families. Upper amount: Up to $200,000 USD over two years. Deadline for proposals: September 15, 2018.
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.


July 12, 2018

  • NEW! ECHO (Entrepreneurship for Cardiovascular Health Opportunity) The Translational Biology & Engineering Program (TBEP) in partnership with the Health Innovation Hub (H2i) at the University of Toronto. ECHO is a specialized hands-on training program led by veteran entrepreneurs and consultants across a variety of sectors. ECHO provides innovators of cardiovascular technologies with entrepreneurship training, mentorship, networking, and funding opportunities. Any Canadian-based student, researcher and/or entrepreneur developing advanced cardiovascular technologies and innovations is encouraged to apply. ECHO is a specialized experiential training program with main objectives to:
    -  Provide entrepreneurship training, mentorship, networking and funding opportunities for early ventures in the cardiovascular health sector.
    -  Aid in transferring research innovations and intellectual property from academic and hospital institutions into the economy.
    -  Create more start-ups in the cardiovascular health sector.
    Based in Toronto, this is a 12-month intensive training program led by high-calibre entrepreneurial industry, policy, regulatory and clinical experts. It comprises a unique combination of five complementary modules. Visit ECHO's website for full program information and enrolment instructions or contact Soror Sharifpoor, TBEP research program manager. Application deadline: August 24, 2018. Interviews will commence September 2018 for selected applicants. The program begins October 1, 2018.
  • Community Partnership Research Program: Pilot Program. Jointly funded by the University and the Connaught Fund. This initiative is intended to help create new collaborative research partnerships, or nurture early stage partnerships, between the University and community partners, fostering access to each other’s unique knowledge, expertise and capabilities on issues of shared interest that, over time, may evolve into more established relationships that will attract external funding through, for example, the SSHRC Partnerships Grant program. Partnership Projects can request up to $50,000 per year for one to three years. University of Toronto faculty members who are eligible to hold research funding are eligible to submit proposals in response to this call.  Proposed initiatives must include an organizing team that includes representatives of a lead community partner, including a co-leader for the initiative. Contact: Steven Hermans, Partnership Development Officer; Tel: 416-946-3606. Application Deadline: October 31, 2018. CPRP Program Guidelines and CPRP Application Instructions.
  • Sanofi-Pasteur-University of Toronto-Université Paris-Descartes International Collaborative Research Pilot and Feasibility Grant Program. Broadly focused in the fields of diabetes, lipids, and metabolism, this competition is open to basic science, clinical, or translational research applicants. Eligible topics include disease complications, beta cells, insulin resistance, obesity, and cardiovascular disease. The proposals must involve at least two investigators, one from each academic institution (Toronto, Paris-Descartes), who are eligible to hold independent research funding. The program will fund up to 2 proposals, each with a maximum total Year 1 budget of $60K and the potential for a Year 2 budget of between $30K and $60K. Questions may be directed to Christopher Yip, Associate Vice President, International Partnerships. Application deadline: August 31, 2018 at 4pm.
  • CIHR Foundation Grant Program Update. A message from Michel Perron, Executive Vice-President, CIHR, July 9, 2018.
    Details for the 2018-2019 CIHR Foundation Grant Program are now available on ResearchNet.
    Registration deadline: August 15, 2018; Application deadline - Stage 1: September 9, 2019.
  • CIHR Catalyst Grant - Cannabis Research in Urgent Priority Areas: PRE-LAUNCH. In response, several CIHR Institutes and partner agencies have led focused consultations aimed at identifying the most urgent priority areas for cannabis research. This included a multi-institute Research Needs and Priorities Workshop that brought cannabis researchers together with stakeholders from federal departments, regulatory bodies and other relevant organizations. As a result, several health research gaps were identified in order to ensure a comprehensive and coordinated approach to future research on the potential benefits and/or risks of cannabis use in different populations. The purpose of this current funding opportunity is to strengthen the evidence base and expand cannabis research in these identified areas, to build research capacity and/or to inform the development of future larger scale research projects. Registration date: September 2018; Application deadline: October 2018.
  • CIHR Catalyst Grant: Post-traumatic Stress Injuries in Public Safety Personnel: PRE-LAUNCH. Building on previous investments in brain and mental health research, CIHR-INMHA is launching the Post-Traumatic Stress Injuries in Public Safety Personnel (PSP) funding opportunity to catalyze research projects that have a primary focus on understanding, identifying, mitigating and/or preventing PTSI and adverse mental health outcomes among PSP. This funding opportunity will support applications that are determined relevant to one or more priority areas. Application deadline: September 2018.
  • CIHR Transitions in Care: Component 2 - Best and Wise Practices: PRE-LAUNCH. The focus of the Best and Wise Practices Grants is to support groups of researchers and knowledge users to identify best and wise practices in two (2) or more of the identified TiC focus areas. The grants will also provide support to groups that require additional evidence gathering and/or the building of relevant relationships and partnerships to address challenges, gaps and/or barriers related to improving care transitions and mitigating negative patient outcomes resulting from poor transitions. Program launch: Summer 2018; Anticipated deadline: Fall 2018.
    WEBINAR: July 19, 2019 from 1pm - 2pm EDT. Register online.
  • IMPORTANT CHANGES: CIHR Antimicrobial Resistance: Point of Diagnostics - Phase 2. Full program details in ResearchNet.
    • The application deadline has been pushed from August 15, 2018 to now October 2, 2018.
    • The following section has been REMOVED from the funding opportunity text:
      *The following expenses are not eligible for support through this funding opportunity:
      • Stipends for trainees
      • Randomized Controlled Trials
      • Research not directly related to the objectives of this Funding Opportunity
  • NCE: AGE-WELL - 2018 SIP Accelerator Program. AGE-WELL is dedicated to the creation of technologies and services that benefit older adults and caregivers. Our aim is to help older Canadians maintain their independence, health and quality of life through technologies and services that increase their safety and security, support their independent living, and enhance their social participation. This funding program supports innovative post-discovery projects focused on the commercialization and/or knowledge mobilization of solutions (e.g. technologies, services or policies) aligned with AGE-WELL’s mission and vision. Amount: Up to $40,000 over 12 months. Award winners can re-apply for renewal funding in a future call for proposals, pending end-of-term review. Sponsor deadline: August 10, 2018.
  • Cystic Fibrosis Canada: Basic Research Grants and Clinical Research Grants programs. The purpose of Cystic Fibrosis Canada’s fall research competition is to support leading research into the understanding, management and treatment of, and cure for, cystic fibrosis (CF).  Proposals will be scored on both scientific merit and impact for CF patients. All applications must address Cystic Fibrosis Canada’s Core Principles of funding the best science that has the highest probability of making an impact for CF patients. The maximum grant request for basic science and clinical research grants is $100,000 per year for 3 years. Cystic Fibrosis Canada will accept budget requests beyond $100,000/year if there is a funding partner. *Please note that, this year, basic science and clinical research grants will undergo review by separate, expert panels. Deadline for Letters of Intent: August 3, 2018; Full application deadline: October 1, 2018.
  • Muscular Dystrophy Canada: 2018 Seed Grants - DEADLINE EXTENDED. Muscular Dystrophy Canada is pleased to announce an official extension to the submission deadline for the 2018 seed grants for Neuromuscular Disease research. All applications are now due by July 27th 2018 at 11:59 PM (EDT). Please note that if you already submitted your application you are allowed to resubmit it within the new deadline. . If you have any questions or concerns, please contact Marie-Hélène Bolduc, Director of Research and Mission Operations.  View the Request for Proposals.
  • American Foundation for Suicide Prevention.
    • Focus Grants - Blue Sky Research Grant (NEW): Innovative projects in new areas of investigation with potentially high impact for the understanding and prevention of suicide. Open to all fields of inquiry and not limit to studies conducted in the U.S. Deadline for Letters of Intent: August 1, 2018.
    • Innovation Grants: The Foundations offers six innovation grants including: Linked Standard Research Innovation Grants (Deadline for LOIs: September 15, 2018); Distinguished Investigator Innovation Grants; Postdoctoral Research Fellowship Innovation Grants; Standard Research Innovation Grants; Young Investigator Innovation Grants; and Pilot Innovation Grants. All other deadlines: November 1, 2018.

June 22, 2018

  • Minister of Health announces Dr. Michael J. Strong as new President of the CIHR (June 20, 2018). The Honourable Ginette Petitpas Taylor, Minister of Health, announced that Dr. Michael J. Strong has been appointed the new President of the Canadian Institutes of Health Research (CIHR). Dr. Strong is an internationally recognized researcher specializing in the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. He will take up his position on October 1. Dr. Strong’s research focuses on understanding the cellular biology of ALS. His work has helped shed new light on a process by which an abnormal form of some proteins may accumulate in nerve cells in the spinal cord and brain, destroying the cells, and leading to the symptoms of the disease. Dr. Strong will bring extensive leadership experience to CIHR, having served since 2010 as the Dean of the Schulich School of Medicine & Dentistry and Distinguished University Professor at Western University, where he holds the Arthur J. Hudson Chair in ALS Research. From 2000 to 2010, he served as the Chief of Neurology and Co-Chair of the Department of Clinical Neurological Sciences at the London Health Sciences Centre and Western University. Read the full new release.
  • Tri-Council Statement on Self-Identification Data Collection in Support of Equity, Diversity, and Inclusion. Government of Canada Open Letter to the Research Community. The Government of Canada is pleased to inform you that the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC) will now ask all applicants to grant, scholarship, and fellowship programs to provide information on their age, gender, Indigenous identity, and/or status as a member of a visible minority group, and/or as a person with a disability.  Starting this summer, SSHRC and NSERC are asking all applicants for funding competitions (grants, scholarships, and fellowships) to self-identify with information on age, gender, Indigenous identity, and status as a member of a visible minority group or person with a disability. CIHR has also recently implemented this requirement. Read more. Further information on the Self-Identification Data can be found here.

  • CIHR/SSHRC/the International Development Research Centre (IDRC): Call for Proposals - Rapid Research Fund for Ebola Virus Disease Outbreaks.  The Call aims to support social science and humanities, population and public health and/or health systems research to increase collaboration and adaptive scaling of past evidence-based interventions that have proven successful in curbing Ebola Virus Disease transmission, promote novel approaches to remaining challenges, and link existing resources and expertise across the globe to inform the response to the outbreak of Ebola Virus Disease that started in April 2018 in the Democratic Republic of the Congo (DRC), as well as inform prevention and response to future outbreaks of Ebola Virus Disease and other similar diseases.

    Specific aims of the Call are to enhance the mobilization of interdisciplinary teams of Canadian and African health and social scientists and humanists, as well as knowledge users, to help contain the current Ebola Virus Disease outbreak in the Democratic Republic of the Congo (DRC), and prevent or mitigate the impact of future Ebola Virus Disease and similar threats to the region. Deadline to apply: July 13, 2018.
  • CIHR PRE-ANNOUNCEMENT: Evaluations of Interventions to Address the Opioid Crisis - Operating Grants. This funding opportunity will support the evaluation of promising health interventions and practices that have been implemented municipally, provincially and/or nationally to address the opioid crisis relevant to one or more of the four pillars of the Canadian Drugs and Substances Strategy (CDSS). To address the pressing intervention-related evidence needs of knowledge users and increase the application of knowledge in health care and/or health services policy and practice, this funding opportunity requires that at least one participant must be a Knowledge User that is involved in the intervention being evaluated. The total amount available for this funding opportunity is $ 1,500,000, enough to fund approximately 15 grants. Program Launch: June 2018; Registration date: August 2018; Deadline for full applications: September, 2018.
  • LG Chem Global Innovation Contest (GIC 2018). This program is a platform for research collaboration designed by LG Chem that will be initiated with novel proposals from universities and research institutions from all over the world. Please visit their website for specific keywords for GIC 2018, or visit UofT funding opportunities webpage. Nominees of this contest can earn up to $150,000 each for multi-year research activities and may also have the opportunity to collaborate with R&D teams in LG Chem to realize their proposed solutions. Deadline for submission of proposals: September 30, 2018.
  • Department of Defense: Congressionally Directed Medical Research Programs. Various deadlines.
  • Alex's Lemonade Stand Foundation: Familial RUNX1 Research Program. ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The objective of the Familial RUNX1 Research Program, presented by the Babich family Foundation, is to fund research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML. Upper amount: USD $250,000 over two years. Deadline for Letters of Intent: July 2, 2018

June 15, 2018

  • Tri-Agency Research Data Management Policy - CONSULTATION ON DRAFT. The three federal research funding agencies—CIHR, NSERC, and SSHRC, have developed a draft Tri-Agency Research Data Management Policy, which aims to support Canadian research excellence by fostering sound digital data management and data stewardship practices. The draft policy includes suggested requirements related to 1. Institutional data management strategies; 2. Researcher data management plans; and 3. Data deposit. The agencies have invited institutions, associations, organizations and individuals to comment on the draft policy and its usefulness in advancing data management practices in Canada. Feedback will inform the final design of the policy, which the agencies plan to launch in 2019.  The feedback period will run until August 31, 2018. 

    We encourage members of the University community to provide their own input directly to the email addresses on the Tri-Agency website, and to share their submission with us if possible at vpri.reports@utoronto.ca.
    It is important that there be broad input from as broad a range of disciplines as possible to reflect the unique aspects of data management in different areas of scholarship.  Given the importance of data management for the University of Toronto community, we will be submitting an institutional response to the call for feedback. Additional information can be found in the agencies' Frequently Asked Questions (FAQs)
  • CIHR Launches Transitions in Care Initiative. The Transitions in Care (TiC) initiative is a multi-Institute initiative that aims to improve the health and wellness of Canadians by supporting research that transforms the health system to optimize the outcomes of individuals experiencing transitions in care.
    WEBINAR: July 5, 2018 from 2pm - 3:30pm EDT. Register here.
  • NSERC Discovery Grant NOI: INFORMATION SESSION. In order to apply for a Discovery Grant in November 2018, an applicant MUST complete and submit an online Notice of Intent by 8 pm EST on August 1, 2018. If you do not submit a Notice of Intent by the deadline, you will NOT be eligible to apply in November for a Discovery Grant. In addition,  UofT Research Services will be holding an information session on Wednesday July 18, 2018 from 1pm to 3pm in BA 1220, Bahen Centre, 40 St George St. Please RSVP by July 13th, 2018 to Teresa.Trimboli@utoronto.ca, RFA, Research Services; 416-978-2525. Topics covered in the session include the Notice of Intent, program requirements, eligibility requirements, changes for this year’s competition (Research Portal and Canadian Common CV), evaluation criteria and proposal development. 
    For submission details please UofT Research Services webpage, as well as the NSERC Discovery Grants webpage.
  • PRE-ANNOUNCEMENT: Canadian Microbiome Initiative 2 (CMI2): A Focus on Function and Translation Research Teams. The overall goal of the CMI2 is to enable the development of effective preventative and therapeutic interventions through a deeper understanding of the role of microbiome in human health. The upcoming competition will support Research Teams to develop new knowledge on the causational roles of microbiome in human health and disease which will lead to the development of new preventative and therapeutic interventions. The total amount available for this funding opportunity is $14,350,000. This amount may increase if additional funding partners participate, enough to fund a minimum of 7 grants. Additional funding is available through Mitacs to fund internships for graduate students and post-doctoral fellows in CMI2 funded projects. Anticipated launch date: Summer 2018.

  • NSERC Idea to Innovation (I2I): Commercialization Grants. Four times per year, the NSERC accepts applications for its “Idea to Innovation” (I2I) program, for the purpose of accelerating pre-competitive technologies for transfer to a Canadian company. Successful applicants receive awards of up to $125,000 for each phase of their commercialization project, with additional funding available as the project progresses. Applicants can apply to various phases of the I2I program. For more information contact innovations.partnerships@utoronto.ca or visit NSERC`s websiteUofT Internal application deadline for current round: Friday, June 22, 2018; Sponsor deadline: July 3, 2018.

  • Explore partnering with Sanofi Pasteur: Development and production of human vaccines, both prophylactic and therapeutic, including vaccines for chronic infectious diseases. Interest list here.

  • Gilead Sciences Research Scholars Program in Cystic Fibrosis. This program supports innovative science research that will advance knowledge in the fields of pediatric and adult cystic fibrosis. The awards provide financial support to 3 junior faculty researchers in Canada, Europe, or the United States for a 2 year period. Each award is funded up to USD $130,000 over two years. Deadline for submissions: July 20, 2018.
  • Autism Speaks: 2018 Treatment Research Grants. Autism Speaks invites Treatment Research Grant applications to conduct innovative studies of novel treatments and interventions for people with autism spectrum disorder (ASD) throughout the life span. These may include medical approaches such as pharmacological treatments and complementary and alternative forms of health care, as well as behavioral and/or psychosocial interventions. Maximum amount: $250,000 per year for up to 3 years, with a maximum of $750,000 per award. Deadline for Letters of Intent: July 18, 2018.
  • National Multiple Sclerosis Society (NMSS): Collaborative MS Research Centre Awards. The following focus areas are critical to advancing breakthroughs that will identify solutions for people living with MS today and ultimately lead to prevention and a cure: Define the contribution of genetics, risk factors and their modifiers to the risk for developing MS and disease course, and develop strategies to prevent, treat and cure all forms of MS; Understand MS pathology and pathophysiology; Understand and treat MS progression; Identify strategies for neuroprotection and nervous system repair; and Elucidate the cause of MS symptoms, the impact of comorbidities, and identify rehabilitation, wellness behaviors and lifestyle approaches. Upper amount: USD $750,000 over five years. Deadline for pre-applications: August 30, 2018.
  • Cerebral Palsy Alliance: Career Development Grants. These are unrestricted grants to be used by the award recipient for any of the activities as listed below to assist in the recipient's career pursuits. Applicants must ensure their project addresses the Research Foundation's priorities: Aetiology, causal pathways; Prevention; Early identification, early intervention; Novel interventions, novel treatments; and Cure. Upper amount: AUD $250,000. Deadline for submissions: August 31, 2018.
  • Wings for Life (WLF) Spinal Cord Research Foundation. 
    • Project Research Grants:  Research projects may address all aspects of spinal cord lesions, nerve regeneration, trophic support of injured neurons and functional changes induced by lesions (preferentially in mammals). Proposals should have a view to translation from the laboratory to the clinical setting and have the potential to provide real benefits to human patients.  Clinical research projects can be situated in the fields of diagnosis, acute lesion management (including surgery), neurology, urology, rehabilitation and other areas related to paraplegia. Deadline for preliminary proposals: September 2, 2018.
    • Individual Research Grants: This grant is intended only to cover the salary of the applicant: Post-docs, PhDs, and/or technicians. The goals of the individual research grant program are to encourage new investigator's work on regeneration and recovery processes and to encourage researchers to develop new ideas and/or to transfer their efforts of other areas into spinal cord research.  Deadline for preliminary proposals: September 2, 2018.


June 4, 2018

  • Annual Faculty of Medicine Grant Writing Workshop 2018. Join us to learn more about services available through the Office of the Vice Dean, Research & Innovation; Behind the scenes of grant review panels; and Grant Writing and Development. This event is freee to faculty, staff and post-doctoral fellows. Further details here. Poster.
    Date: Tuesday, June 26, 2018 from 9am - 12pm
    Location: Medical Sciences Building, Room 3153, 1 King's College Circle
    RSVP by June 22nd: https://medicine.utoronto.ca/form/annual-faculty-medicine-grant-writing-workshop-2018
  • New resources for U of T Inventors and Entrepreneurs. The Innovations & Partnerships Office (IPO) is pleased to provide two new resources for faculty, researchers, and students interested in commercializing research or starting a company: The Inventor's Guide to Technology Transfer and the Start-Up Guide. These guides provide practical information on: When and how to disclose an invention; Protecting intellectual property; Navigating U of T policies and conflict of interest; Getting funding; and Bringing the technology to market. If you or your department have any questions or would like to host a workshop to learn more, contact commercialization@utoronto.ca.
  • CIHR: Epigenetics Clinical Translation (Funding Opportunity and Webinar). This funding opportunity is a key component of the second phase of the Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC), a multi-agency, pan-Canadian initiative led by CIHR. The current funding opportunity is to support research regarding epigenetics in the clinical setting, demonstrating proof-of-concept utility of epigenetic changes in the context of diagnostics and potential therapeutic targets, in addition to building and fostering partnerships with relevant patients and stakeholders. More information about this funding opportunity is available on ResearchNet. To support applications in this area, an information webinar is being held June 13, 2018 at 1:00 p.m. (EDT). Participation in the webinar is not required to submit an application, but it is encouraged. A recording of the webinar and slides will be available upon request after the webinar for those unable to attend. Registration deadline: September 5, 2018; application deadline: October 10, 2019.
  • CIHR Pre-Announcement: Canadian Microbiome Initiative 2 (CMI2): A Focus on Function and Translation Research Teams. The upcoming competition will support Research Teams to develop new knowledge on the causational roles of microbiome in human health and disease which will lead to the development of new preventative and therapeutic interventions. Full details for this funding opportunity will be available on ResearchNet soon.
  • CIHR: Sex, Gender and Health Research (Video). Assessing Sex and Gender in Peer Review learning video is now available.
  • Pre-Announcement: Rapid Research Response to the DRC Ebola Outbreak. The Government of Canada, through CIHR, SSHRC and the International Development Research Centre (IDRC), is now working in partnership with the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and other international agencies to launch a rapid research response. They intend to make available a combined $1.5 million CAD to support partnered teams of Canadian and African researchers to conduct health services research, population health research and/or social science research in the context of this particular health emergency. The full Request for Applications is expected to be posted in 2-4 weeks, after which eligible researchers will have approximately four (4) weeks to submit short applications for peer-review. Applicants will be expected to justify why their proposed research requires this rapid response funding and cannot wait for regular funding opportunities made available through CIHR, SSHRC or IDRC.
  • Simons Foundation: Genomic Analysis for Autism Risk Variants in SPARK. Grants awarded through this RFA are intended to advance our understanding of the genetic basis of autism. Investigators who are interested in analyzing genomic data in innovative ways from thousands of SPARK families are encouraged to apply. Available data will include whole-exome and genome-wide genotyping data from approximately 4,500 individuals with autism spectrum disorder (ASD) and their biological parents. Approximately half of these families will also have genomic data from an unaffected sibling. In addition, whole-genome sequencing data will be available from approximately 400 other ASD individuals, plus their biological parents and unaffected siblings. A limited phenotypic dataset for all participants will be available. Upper amount: $100,000 USD over 18 months. Deadline for Notice of Intent: June 22, 2018; Full proposal deadline: July 27, 2018.
  • Solving Kids' Cancer: Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research. The TDI's goal is to support innovative clinical studies that are high on the risk/reward spectrum while, at the same time, investigating these research questions efficiently and effectively. Priority is given to proposals that introduce therapeutic agents and modalities which are first-in-children and have a strong potential to improve treatment outcomes. The TDI of SKC only supports clinical research. The organization specifically focuses on novel clinical studies for neuroblastoma, brain tumors and sarcomas. Upper amount: $600,000 USD for up to two years. Deadline for preliminary proposals: Continuous.
  • Vasculitis Foundation: Research Program. The VF Research Program provides one- or two-year seed grants to support pilot studies in researching: Etiology/Pathogenesis; Epidemiology, including genetics; Diagnosis, including identification of disease subtypes; and Treatment/Management, including therapeutics to treat vasculitis or prevent complications, bio markers, and psychosocial outcomes. Maximum amount: $50,000 USD over one or two years. Deadline for Letters of Intent (new): June 15, 2018.

    SPECIAL REQUEST FOR PROPOSALS:  The Vasculitis Foundation is partnering with the Swiss Foundation for Research on Muscle Diseases, Cortaillod, Switzerland, to fund research on Polymyalgia rheumatica.  To learn more about this special funding opportunity, please contact Joyce Kullman, VF Executive Director:  jakullman@vasculitisfoundation.org
  • Alzheimer's Drug Discovery Foundation (ADDF): Accelerating Drug Discovery for Frontotemporal DegenerationThe ADDF and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this request for proposals. Funding priorities: 1) Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME. 2) Testing of novel lead compounds, biologics, or repurposed drug candidates in relevant animal models for in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies. Average award amount: $100,000 - $150,000 USD. Deadline for Letters of Intent: July 13, 2018.
  • Histiocytosis Association: Request for Research Proposals. Proposals for scientific research are accepted for studies into the causes, mechanisms, and improved means of treatment for histiocytic disorders. Proposals are evaluated on the basis of science, feasibility, and relevance. All proposals are expected to address one or more of the histiocytic disorders. Upper amount: $50,000 USD. Deadline for proposals: July 1, 2018.
  • Kennedy's Disease Association. The Kennedy's Disease Association (KDA) is planning to fund one or more research grants this fall to further the understanding of the pathological mechanisms of Kennedy's Disease. Applications from junior investigators and from senior post-doctoral fellows are encouraged. Upper amount $50,000 USD. Deadline for proposals: July 30, 2018.
  • Global Lyme Alliance (GLA): Research Grant Award Program. GLA encourages proposals for the 2018-19 Research Grant Award Program that explore regulation of Lyme disease and other tick-borne disease pathogenesis, with an emphasis on the role of an individual's microbiome as well as genetic and epigenetic factors that might inform a "personalized medicine" approach to treatment. Proposals in other topical areas related to Lyme and other tick-borne diseases also will be accepted. Small-scale grants for proof-of-concept studies lasting one year, can be requested for between USD $50,000 and $100,000. Full-scale grants may request larger amounts, up to USD $175,000 per year to be spent over the course of a two to three-year period of funding. Deadline for proposals: August 1, 2018.
  • Leukemia & Lymphoma Society: Specialized Centre of Research (SCOR) Program. The objective of the SCOR grant program is to enhance the development of innovative strategies for the treatment, diagnosis, or prevention of hematological malignancies. Upper amount: $1,000,000 per year for five years. Deadline for Letters of Intent: August 31, 2018.
  • Leukemia & Lymphoma Society: Translational Research Program. LLS supports research, patient aid, community service programs, advocacy, and public and professional education. The formation of the Translational Research Program (TRP) was to foster collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness. Awards are limited to an annual maximum of $200,000 USD for years. Two additional years may be available through a competitive, peer-review renewal. Deadline for Letters of Intent: August 31, 2018.
  • National Organization for Rare Disorders, Inc. (NORD): Rare Disease Research Grant Program. The purpose of the NORD Rare Disease Research Grant Program is to encourage meritorious scientific and clinical studies designed to improve the diagnosis or therapy of rare "orphan" diseases. Grants will be awarded to academic researchers to initiate small scientific research studies or clinical trials. Deadline for applications: July 16, 2018.
    • Alveolar Capillary Dysplasia with Misalignment of the Pulmonary Veins (ACD/MPV)
    • Appendix Cancer and Pseudomyxoma Peritonei (PMP)
    • Familial Hypercholesterolemia 
    • Malonic Aciduria 
    • New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) 
    • PACS1-Related Syndrome (Schuurs-Hoeijmakers Syndrome)
    • Primary Orthostatic Tremor 
  • Jain Foundation. Research for the dysferlinopathies (LGMD2B and Miyoshi Myopathy). The Foundation funds research using a non-traditional funding model. The explicit goal of the Foundation is to expedite development of a treatment or cure for the dysferlinopathies (LGMD2B and Miyoshi Myopathy).  The project must have direct relevance to dysferlin deficiencies - either to extend the understanding of the disease or a unique approach to a treatment for the disease. The project should not have been previously performed elsewhere and sufficient due diligence should have been done to find out if the same project is currently being done in another lab. Deadline for preliminary proposals: Continuous.
  • MedEvac Foundation International: Grant Program. The Foundation awards funds to support the development of research and education in air medical and critical care ground transport. Grants are available to any person who is qualified to conduct research in the critical care transport industry for the proposed funding year. Visit their website for the Foundation's priorities for their 2018 grant cycle. Deadline for applications: August 3, 2018. 


May 24, 2018

  • NSERC Discovery Grant NOI webinars. NSERC has announced a number of webinars for the 2018 competition for NSERC Discovery Grant. The webinars will highlight how to submit a NOI using the Research Portal and the NSERC Canadian Common CV (CCV)
    ENGLISH: June 19 and July 12 from 1pm-3pm ET
    FRENCH: June 21 and July 10 from 1pm-3pm ET 

    Conference # 1 877-413-4790; Conference ID: 7462843; Link: https://nsercofcanada.adobeconnect.com/_a1139318731/complete-application/ 

    In order to be better prepared for these webinars, NSERC invites you to familiarize yourself with the following documents:
  • Council of the Great Lakes Region Presentation and Discussion. The Council of the Great Lakes Region (CGLR) seeks to engage with U of T researchers. Mark Fisher, President and CEO of the CGLR, will be conducting an information session at U of T to present and discuss the Council’s work. This session is open to any faculty member from any department who is interested in finding out more about the CGLR and about potential involvement in the Council's research projects and events. Launched in 2013, the CGLR brings all levels of government in the Great Lakes Region together with industry, academia, and the broader non-profit sector in order to create a stronger and more dynamic culture of collaboration across the border and key sectors. Its main activities include conducting public policy research, convening dialogues, and advocacy, with a focus on fully harnessing the region's economic strengths and assets, improving the well-being and prosperity of its citizens, and protecting the environment for future generations. 
    Date: June 19, 2018, 10am - 11am
    Simcoe Hall, 27 King's College Circle, President's Boardroom, room 132
    Video and teleconferencing arrangements will be made for those who require it.
    If you would like to attend, please RSVP to events.vpresearch@utoronto.ca.
    For more information on the CGLR
  • Banting Research Foundation - Executive Director Position. The Banting Research Foundation is seeking a part-time Executive Director to manage all activities of the Foundation, including its annual grant program. The position reports to the Board of Trustees, and executes all policies and decisions of the Board. A science background and business administration experience, preferably in the not-for-profit/charity realm, are important. Knowledge of fundraising procedures is an asset. This role is broad in scope and suits someone comfortable with working independently with minimal day-to-day direction. Please see the position description for details of the role.
    Contact: info@bantingresearchfoundation.ca
  • The Terry Fox Research Institute (Terry Fox Foundation): 2019 Research Programs.
    • The Terry Fox New Frontiers Program Project Grants support multidisciplinary teams of excellence that contribute to well-defined research topics of relevance to cancer. Deadline for Letters of Intent: July 13, 2018.
    • The Terry Fox New Investigator Awards support outstanding young researchers as they develop their careers as independent research scientists or clinician scientists to undertake high-quality cancer research while in close collaboration with established TFRI-funded research teams. Deadline for applications: July 30, 2018.
  • Neuroendocrine Tumor Research Foundation (NETRF). NETRF Grant Funding Opportunities. NETRF is seeking investigators and teams of investigators from around the world, with the tools to study neuroendocrine cancers in new ways. The foundation is very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts in bioinformatics, bio-nanotechnology, or other relevant disciplines. Proposals that cover promising and potentially transferable mechanisms and/or technologies, which have been applied successfully to other areas of cancer research, are highly desirable, and will be evaluated based on their level of applicability to NETs. While NETRF will continue to fund research in pancreatic and gastrointestinal NETs, this year it also invites grants that propose to study typical or atypical lung carcinoids. The deadline for Letters of Intent is June 15, 2018.
    • Accelerator Award: 4-year grant in the amount of $1,200,000 USD ($300K per year)
    • Petersen Investigator Award: 2-year grant in the amount of $300,000 USD ($150K per year)
    • Pilot Project Award: 1-year grant at either $50K or $100K USD/year
  • American Association for Cancer Research (AACR): Stand Up to Cancer T-Cell Lymphoma Dream Team Translational Research Grant. This research grant will fund a translational cancer research project focused on T-cell lymphoma that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). To maximize creativity, innovation, and collaboration, the Dream Team must include laboratory and clinical researchers, senior and/or young investigators, and senior scientists who have not worked together in the past. Amount $8,000,000 USD over 3 years. Deadline for Letters of Intent: July 2, 2018.
  • Saving Tiny Hearts Society: Research Grants. The Society awards research grants to early stage science with unique hypotheses fostering the next generation of congenital heart defect research creating a strong foundation of preliminary evidence to make scientific advancements. Priority will be given to well-designed hypothesis driven research that will impact the lives of children and adults living with congenital heart disease. Amount: Up to $75,000 USD for a single year grant. Deadline for applications: July 16, 2018.
  • A-T Children's Project: Investigator Initiated Grants. The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T. Applicants please note that unless specific Requests for Applications are present, the A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on: pre-clinical research and clinical studies. As such, these types of applications will be given priority funding. One- and two-year projects are funded up to a maximum total direct cost of US$75,000 per year. Budgets for up to US$150,000 for a two-year project are acceptable. Deadline for Letters of Intent: August 1, 2018.
  • JDRF: Strategic Research Agreements. Available funding for the Strategic Research Agreements will be reviewed on a per-application basis. The deadline for Concept Paper/Proposal for each program is August 1, 2018 or November 1, 2018.
    • Strategic Research Agreements - Clinical SRA Projects are intended to support research programs that qualify under the JDRF clinical review process. This funding mechanism is intended to support early-stage clinical trials to test therapeutic approaches as well as non-interventional patient oriented studies that are intended to lead to the development of clinical interventions and monitoring tools (such as markers) for diabetes and its complications. 
    • Strategic Research Agreements - Multi-Project SRA provides a mechanism to stimulate new collaborations between clinical and basic scientists and/or between scientists from diverse backgrounds as a means to conceive and develop new approaches to major challenges, potential breakthroughs, or persistent obstacles to progress along the various paths to prevent, treat or cure Type 1 diabetes and its complications.
    • Strategic Research Agreements - Single Project. JDRF's Strategic Research Agreements were created to provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The Strategic Research Agreement is a partnership between Investigator(s) and JDRF Scientists to help address roadblocks and accelerate JDRF's mission through support of cutting-edge scientific investigation.
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.
    • Targeted In Vivo Delivery of Gene Therapeutics for HIV Cure (R01)
    • Novel Nucleic Acid Sequencing Technology Development (R01) and (R21)
    • BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01)
    • In Vivo Synaptic Function in Alzheimers Disease and Related Dementias (R21)
    • Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
    • Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33)
    • Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33)
    • Harnessing Big Data to Halt HIV (R01)
    • Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01)
    • BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01)
    • Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01) and (R21)
    • Understanding Skeletal Effects of Type 1 Diabetes (R01)
    • International Research Collaboration on Drug Abuse and Addiction Research (R01)
    • Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34)
    • Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34)
    • Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01)
    • Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34)
    • Novel Genomic Technology Development (R01) and (R21)
    • Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (UM1)
    • Precision Imaging of Oral Lesions (R01) and (R21)
    • Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01)



Back to Top